title: How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future.
abstract: Several decades of research on human cytomegalovirus (HCMV) and the principal mammalian cytomegaloviruses which to varying degrees act as models of HCMV infection, particularly murine, guinea pig and rhesus CMV, have led to the recognition of the CMVs as interesting models of persistent infection with a large and complex DNA virus, which have been highly informative of the immunology and molecular pathogenesis of the virus-host relationship in the normal host. However, it is appropriate to ask how this relative wealth of knowledge has influenced the understanding and management of clinical disease due to HCMV. This article considers the immunology of cytomegalovirus in the normal human host, and the interrelated issue of the sites of HCMV latency and mechanisms of reactivation in the myeloid cell lineage, and in related in vitro model systems. The way in which this site of latency conditions the immune response, and emerging information on the special features of the adaptive immune response to HCMV during latency are also considered. Examples of HCMV disease associated with acquired immunosuppression, principally in the context of transplantation, but also as a consequence of HIV/AIDS and immune reconstitution inflammatory syndrome, are then discussed, with a particular emphasis on how understanding the immunology of persistent infection may contribute to managing CMV disease now and in future.
authors.affiliation: Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK, jgps10@medschl.cam.ac.uk.
authors.forename: J G Patrick
authors.initials: JG
authors.lastname: Sissons
authors.forename: Mark R
authors.initials: MR
authors.lastname: Wills
mesh_terms: D056704:Adaptive Immunity; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy / Q000821:virology*; D019468:Disease Management; D006801:Humans; D007113:Immunity, Innate; D016867:Immunocompromised Host; D016219:Immunotherapy, Adoptive; D022423:Myeloid Cells / Q000821:virology; D013601:T-Lymphocytes / Q000276:immunology; D014775:Virus Activation / Q000276:immunology; D017735:Virus Latency / Q000276:immunology